Search PubMed⌕ Search

Biomedical subjects

Y Nakagami

Publications and source records attributed to Y Nakagami.

63 records · Page 4Linked to original sources
PubMed1983

[Studies on human prostatic carcinoma cell lines: evaluation of acid phosphatase productivity and effects of sex hormones on the cells].

The established cell lines from human prostatic cancer, such as Duke 145, 8PC93, and 19PC93, were examined in terms of their producing activity of acid phosphatase (ACP) and sensitivity to sex hormones. The results obtained are summarized. 1. ACP producing activity ACP was estimated with phenyl phosphate as a substrate. Values of the materials from each of the cells extracted with 5% Triton X-100 were Duke 145 (6.1 u/mg), 8PC93 (40.6 u/mg), and 19PC93 (40.4 u/mg), respectively. Activities of ACP were prohibited by the presence of L-tartrate. Histochemistry of ACP was demonstrated by azo-dye staining procedure, revealing the positive reactions in the cytoplasms of 8PC93 and 19PC93 cells, but weak reaction in duke 145 cells. Disk polyacrylamide gel electrophoresis (D-PAGE) was employed for ACP analysis of the cell extracts with 5% Tryton X-100 treatment. Two main bands were observed near original point and at another point proposed as ACP-2. These ACP positive reactions on the gels were also inhibited by the presence of L-tartrate in staining solution. In the case of Duke 145 cell material, the intensity of the reaction was observed weak in those specific two bands. 2. Hormone effects to the cells The prostatic cancer cells were examined in terms of sensitivity to sex steroid hormones such as androsterone, progesterone, estrone, estradiol, and estriol, by a colony formation method. Fifty percent reduction in colony formation of the 8PC93 and 19PC93 cells was found at the concentration of ca. 1.5 micrograms/ml in the case using progesterone or estrone, or estradiol, while 50% reduction of the Duke 145 cells was observed at 5 micrograms/ml only in a case using progesterone.

Acid Phosphatase↗
PubMed1980

Adjuvant immunotherapy with a S. pyogenes preparation (OK432) in urogenital cancer patients.

We evaluated the immunostimulative activity of a Streptococcus pyogenes preparation (OK432) in 50 patients with urogenital carcinoma. Differential lymphocyte blastogenic response to mitogens and quantitation of the lymphocyte subpopulation bearing Fc receptor sites were the two immunoparameters used in this study to assess the status of the cancer-bearing host. Using these immunoparameters, we observed a pattern whereby a substantial deviation from unity in the mitogen reactive ratio and an increase in the number of IgGFcR+T cells were correlated with malignant progression; administration of the immunopotentiator OK432 had a marked effect on immunoparameters reflected by our assays, with a trend toward return to normal values with progression of immunotherapy.

Adult↗
PubMedDate not supplied

A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine.

A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985. In 1987, his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with 131I-metaiodobenzylguanidine (MIBG) showed multiple bone and liver metastases. He was treated twice with infusions of 3.7 GBq of 131I-MIBG. After the first treatment, he had transient hypertension and pain in the back and right leg. Subsequent 131I-MIBG scintigraphy showed that the number of metastatic tumors had decreased. The second treatment was less effective. Excess catecholamines were treated with alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor, at doses between 250 and 2000 mg/day, which significantly decreased urinary NE excretion. This is the first case treated with 131I-MIBG in Japan.

3-Iodobenzylguanidine↗
PubMedDate not supplied

Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1.

BACKGROUND: Mitogen-activated protein kinase (MAPK) is one of the transforming growth factor-beta (TGF-beta signaling pathways while heat shock protein 70 (HSP70) prevents apoptosis by affecting MAPK signaling downstream. However, the interrelationship between TGF-beta and HSP70 signaling is still unknown. MATERIALS AND METHODS: DU-145 prostate cancer cells were treated with 40 pM and 200 pM TGF-beta1. After 3, 6, 9, 12 and 24 hours, cell proliferation assay and cell cycle analysis were performed. The activities of HSP70 and MAPKs (c-Jun N-terminal kinase 1 (JNK1), extracellular signal-regulated kinase 1 (ERK1), ERK2 and p38) were analyzed by Western blot at each time-point. RESULTS: TGF-beta1 inhibited the cell growth in a dose-dependent manner at 3 hours. Late G1 accumulation in the cell cycle was observed in a dose-dependent manner after 24 hours. HSP70 and JNK1 increased only at 3 hours and decreased for up to 24 hours thereafter. ERK1, ERK2 and p38 decreased from 3 to 24 hours after TGF-beta1 treatment. CONCLUSION: These data suggest that HSP70 does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1.

Blotting, Western↗